AIM2在肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2017.02.016

Abstract

Abstract: Absent in melanoma 2(AIM2),as a cytoplasmic DNA sensor,can perceive the cytoplasmic dsDNA which released by the cells infected with DNA virus or bacteria.AIM2 will be raised by Apoptosis-associated speck-like protein containing a CARD to produce inflammation complex,activate of Caspase-1,promote the maturation,and secretion of IL-1β and IL-18,or lead to pyroptosis.AIM2 plays an importation role in initiating immunity.Recent research shows that AIM2 has an influence on the occurrence and progress in tumor,it acts as a tumor suppressor and inhibits tumor progression in liver and breast carcinoma;However,AIM2 shows the carcinogenic effect of promoting tumor development on cervical carcinoma and oral squamous cell carcinoma.These results contribute to the diagnosis and prognosis of malignant tumor.

Key words: AIM2, Malignant tumor, Inflammasome

CLC Number:

HAO Lixiao,ZHANG Yunyan. Research progress of AIM2 in tumor[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 175-178.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2017.02.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2017/V31/I2/175

References

1 DeYoung KL,Ray ME,Su YA,et al.Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma[J].Oncogene,1997,15(4):453-457.
2 Ma X,Guo P,Qiu Y,et al.Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway[J].Oncotarget,2016,7(24):36185-36197.
3 Ponomareva L,Liu H,Duan X,et al.AIM2,an IFN-inducible cytosolic DNA sensor,in the development of benign prostate hyperplasia and prostate cancer[J].Mol Cancer Res,2013,11(10):1193-1202.
4 Chen IF,Ou-Yang F,Hung JY,et al.AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model[J].Mol Cancer Ther,2006,5(1):1-7.
5 Liu ZY,Yi J,Liu FE.The molecular mechanism of breast cancer cell apoptosis induction by absent in melanoma(AIM2)[J].Int J Clin Exp Med,2015,8(9):14750-14758.
6 Wilson JE,Petrucelli AS,Chen L,et al.Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt[J].Nat Med,2015,21(8):906-913.
7 Man SM,Zhu Q,Zhu L,et al.Critical role for the DNA sensor AIM2 in stem cell proliferation and cancer[J].Cell,2015,162(1):45-58.
8 Roberts TL,Idris A,Dunn JA,et al.HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA[J].Science,2009,323(5917):1057-1060.
9 Fernandes-Alnemri T,Yu JW,Datta P,et al.AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA[J].Nature,2009,458(7237):509-513.
10 Hakimi M,Peters A,Becker A,et al.Inflammation-related induction of absent in melanoma 2(AIM2)in vascular cells and atherosclerotic lesions suggests a role in vascular pathogenesis[J].J Vasc Surg,2014,59(3):794-803.
11 Kopfnagel V,Wittmann M,Werfel T.Human keratinocytes express AIM2 and respond to dsDNA with IL-1β secretion[J].Exp Dermatol,2011,20(12):1027-1029.
12 Dombrowski Y,Peric M,Koglin S,et al.Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions[J].Sci Transl Med,2011,3(82):82-91.
13 Akira S,Uematsu S,Takeuchi O.Pathogen recognition and innate immunity[J].Cell,2006,124(4):783-801.
14 Choubey D,Walter S,Geng Y,et al.Cytoplasmic localization of the interferon-inducible protein that is encoded by the AIM2(absent in melanoma)gene from the 200-gene family[J].FEBS Lett,2000,474(1):38-42.
15 Wang LJ,Hsu CW,Chen CC,et al.Interactome-wide analysis identifies end-binding protein 1 as a crucial component for the speck-like particle formation of activated absence in melanoma 2(AIM2)inflammasomes[J].Mol Cell Proteomics,2012,11(11):1230-1244.
16 Chen LC,Wang LJ,Tsang NM,et al.Tumour inflammasome-derived IL-1β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma[J].EMBO Mol Med,2012,4(12):1276-1293.
17 Kondo Y,Nagai K,Nakahata S,et al.Overexpression of the DNA sensor proteins,absent in melanoma 2 and interferon-inducible 16,contributes to tumorigenesis of oral squamous cell carcinoma with p53 inactivation[J].Cancer Sci,2012,103(4):782-790.
18 Kong H,Wang Y,Zeng X,et al.Differential expression of inflammasomes in lung cancer cell lines and tissues[J].Tumor Biol,2015,36(10):7501-7513.
19 Narayan G,Bourdon V,Chaganti S,et al.Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer:identification of candidate amplified and overexpressed genes[J].Gene Chromosome Canc,2007,46(4):373-384.
20 Khosravi S,Wong RP,Ardekani GS,et al.Role of EIF5A2,a downstream target of Akt,in promoting melanoma cell invasion[J].Br J Cancer,2014,110(2):399-408.
21 Gaperov NM,Farkas SA,Nilsson TK,et al.Epigenetic activation of immune genes in cervical cancer[J].Immunol Lett,2014,162(2):256-257.
22 Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
23 龙向淑,吴强,宋方,等.RAS信号途径参与干扰素-α抑制大鼠血管平滑肌细胞增殖[J].基础医学与临床,2014,34(7):882-885.
24 Lee J,Li L,Gretz N,et al.Absent in Melanoma 2(AIM2)is an important mediator of interferon-dependent and-independent HLA-DRA and HLA-DRB gene expression in colorectal cancers[J].Oncogene,2012,31(10):1242-1253.
25 Wang C,Wang X,Su Z,et al.The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth[J].Oncol Rep,2015,34(4):1708-1716.
26 宋启斌,褚玉新,胡伟国.X线照射对THP1细胞中AIM2炎症小体的影响[J].现代免疫学,2014,34(6):466-470.

[1]	ZHOU Suxia, XU Zhihua, GUO Shuling, FAN Ning, XU Lili. Analysis for the prevalence trend of malignant tumor incidence and mortality in cancer registration areas in Qinghai Province from 2014 to 2021 [J]. Journal of Practical Oncology, 2025, 39(5): 381-387.
[2]	LIU Yang, WANG Ying, MA Xiang, SONG JiaBao, LIU DaMin, CHEN Lili. Analysis of incidence and mortality of malignant tumors among urban residents in Yingkou City,Liaoning Province in 2021 [J]. Journal of Practical Oncology, 2025, 39(5): 400-404.
[3]	DAI Xiaoze, MA Yuxia, LI Yuting, QI Xiaoqing, ZHU Tiancen, MU Huijuan, LIU Hui. Analysis of the incidence and mortality trends of malignant tumors among urban residents in Fuxin City,Liaoning Province from 2014 to 2020 [J]. Journal of Practical Oncology, 2025, 39(4): 278-283.
[4]	ZHU Tiancen, LI Yanxia, REN Fanghan, DAI Xiaoze, LIU Yang, MU Huijuan. Analyses for the epidemic situation of malignant tumors in cancer registration areas of Liaoning Province in 2021 [J]. Journal of Practical Oncology, 2025, 39(4): 294-300.
[5]	LI Ji, ZHANG Maorong, YANG Zhao, WEN Hongmei, WU Fuxian, LI Yuntao. Analyses for the incidence and mortality characteristics of malignant tumors in the cancer registration areas of Kunming City,Yunnan Province in 2020 and their trend from 2016 to 2020 [J]. Journal of Practical Oncology, 2025, 39(3): 169-176.
[6]	WEN Xiaoyan, CHEN Li. Comparative analysis of the burden of malignant tumors among the people aged 30 and above in Sichuan province in 2010 and 2020 [J]. Journal of Practical Oncology, 2025, 39(1): 1-6.
[7]	SU Feng, LIANG Lei, DENG Ying, ZHANG Tonglei, WANG Yanping. Analysis of the epidemic characteristics and trends of cancer in Ankang city,Shaanxi province from 2016 to 2020 [J]. Journal of Practical Oncology, 2024, 38(5): 300-305.
[8]	ZHONG Nvjuan, MA Jingyu, XU Zhida. The incidence and mortality of malignant tumors in Fuqing city,Fujian province in 2019 and trend analysis from 2015 to 2019 [J]. Journal of Practical Oncology, 2024, 38(1): 1-6.
[9]	CHENG Jin, WANG Wei. Research progress on retinoic acid-induced proteins in malignant tumors of the digestive system [J]. Journal of Practical Oncology, 2023, 37(6): 502-506.
[10]	ZHAO Shibo, CHEN Yongfeng, LI Huiyi, FU Aizhen. Research status of Agrin involvement in the occurrence and development of malignant tumors [J]. Journal of Practical Oncology, 2023, 37(6): 507-512.
[11]	SONG Shuming, LI Gaiqin, ZHANG Lifeng, XU Kai, MAO Wenjing, ZHANG Guanghui. Epidemiological analysis of inpatients with malignant tumor at the Affiliated Tumor Hospital of Xinjiang Medical University from 2010 to 2020 [J]. Journal of Practical Oncology, 2023, 37(5): 389-394.
[12]	LIU Yuanlin, FENG Li. Research progress in the mechanism of miR-192-5p in malignant tumors [J]. Journal of Practical Oncology, 2023, 37(5): 439-442.
[13]	WEN Hongmei, CHEN Yang, SHI Qingping, ZHU Yunfang, REN Siying, TANG Xian, SHAO Ying, WU Fuxian, LI Yunfei. Analysis of incidence and mortality of malignant tumors in cancer registration areas of Yunnan province in 2018 [J]. Journal of Practical Oncology, 2023, 37(4): 293-300.
[14]	YANG Jianhua, LUO Saimei, LONG Xintian, LI Wei, YANG Birong, YU Longtao, ZHANG Teng, WEN Hongmei. Analyses of incidence and mortality of malignant tumors in cancer registration areas of Yunnan province in 2017 [J]. Journal of Practical Oncology, 2023, 37(1): 6-10.
[15]	MA Jixiong, MA Juhong, ZHUO Hong, LU Zhaoxia, DING Gaoheng, LIU Yuqin. Incidence and mortality of malignant tumors of Baiyin in Gansu province,2018 [J]. Journal of Practical Oncology, 2023, 37(1): 11-16.

Research progress of AIM2 in tumor

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments